New immune booster tested in early breast cancer
NCT ID NCT02950259
First seen Jan 03, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This early-phase study tested whether a new immune-boosting treatment called IRX-2 is safe to give before chemotherapy in people with early-stage breast cancer, including triple-negative breast cancer. Sixteen participants received IRX-2 before their planned chemotherapy and surgery. The main goal was to see if the treatment caused any delays in surgery and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.